Pancreatic Cancer Research

ResearcherHeidelberg UniversityNo recent work listed

Willem Niesen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5691-1274; OpenAlex author ID A5037590276. Sources: OpenAlex.

Their work

Papers
10 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
40
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 4 papers · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 2 papers

Papers 10

  1. Prognostic relevance of the revised R status definition in pancreatic cancer: meta-analysis. First author DOI 10.1093/bjsopen/zrac010↗
  2. Actual Five-year Survival After Upfront Resection for Pancreatic Ductal Adenocarcinoma: Who Beats the Odds? Co-author DOI 10.1097/sla.0000000000004147↗
  3. Clinical presentation and prognosis of adenosquamous carcinoma of the pancreas - Matched-pair analysis with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2021.02.011↗
  4. Local radicality and survival outcome of pancreatic cancer surgery. Co-author DOI 10.1002/ags3.12273↗
  5. Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail. Co-author DOI 10.1002/bjs.10842↗
  6. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. Co-author DOI 10.1002/ijc.31047↗
  7. Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study. Co-author DOI 10.1245/s10434-018-6391-z↗
  8. Correction to: Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study. Co-author DOI 10.1245/s10434-018-6442-5↗
  9. Radical surgery of oligometastatic pancreatic cancer. First author DOI 10.1016/j.ejso.2016.10.023↗
  10. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Co-author DOI 10.18632/oncotarget.10935↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Markus Wolfgang Büchler · 6 shared papers, 2017–2022 · strength 0.71
  2. Oliver Strobel · 6 shared papers, 2017–2022 · strength 0.71
  3. Thomas P. Hank · 5 shared papers, 2018–2022 · strength 0.64
  4. Thilo Hackert · 4 shared papers, 2017–2022 · strength 0.41
  5. Jörg Kaiser · 3 shared papers, 2018–2022 · strength 0.34
  6. Matthias M. Gaida · 2 shared papers, 2021–2022 · strength 0.25
  7. Markus K. Diener · 3 shared papers, 2018–2022 · strength 0.22
  8. Pascal Probst · 1 shared paper, 2022 · strength 0.16
  9. Rosa Klotz · 1 shared paper, 2022 · strength 0.16
  10. Carl-Stephan Leonhardt · 1 shared paper, 2022 · strength 0.16
  11. Philipp Mayer · 1 shared paper, 2021 · strength 0.13
  12. Anna‐Katharina König · 1 shared paper, 2022 · strength 0.12
  13. Martin A. Schneider · 1 shared paper, 2022 · strength 0.12
  14. Mohammed Al‐Saeedi · 1 shared paper, 2022 · strength 0.12
  15. Christoph Springfeld · 1 shared paper, 2022 · strength 0.12
  16. Helmut Frieß · 2 shared papers, 2018 · strength 0.10
  17. Matteo De Pastena · 2 shared papers, 2018 · strength 0.10
  18. Manuela Cesaretti · 2 shared papers, 2018 · strength 0.10
  19. Sjors Klompmaker · 2 shared papers, 2018 · strength 0.10
  20. Frederik Christiaan Berrevoet · 2 shared papers, 2018 · strength 0.10
  21. Mustapha Adham · 2 shared papers, 2018 · strength 0.10
  22. Traian Dumitraşcu · 2 shared papers, 2018 · strength 0.10
  23. Alain Sauvanet · 2 shared papers, 2018 · strength 0.10
  24. Julie Périnel · 2 shared papers, 2018 · strength 0.10
  25. Anastasios J. Karayiannakis · 2 shared papers, 2018 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.